



University of California  
San Francisco

# Introduction to Implementation Science

## *Part 2: Making the Case for Translation*


Adithya Cattamanchi, MD, MAS  
Associate Professor of Medicine  
Co-director of UCSF Implementation Science Training Program

# Making the case for translation

Justify that a health care intervention should be translated into practice, policy or public health

- Frame evidence as a quality of care issue
- Quantify the performance gap
- Link performance gap to an outcome gap

# Assessing the Quality of Health Care



Donabedian A. *JAMA* 1988;260:1743-8

# Evidence translation → Improved Quality of Health Care

## Outcomes\*

- Safety
- Effectiveness
- Efficiency
- Equity
- Patient-centered
- Timeliness

## Examples

- Error rates
- Mortality/morbidity, QoL
- Cost per QALY/DALY
- Subgroup analyses
- Satisfaction
- Access

\* Based on Institute of Medicine Pillars of Health Care Quality

## Measuring Process When Guidelines Exist

- Guidelines serve as external benchmarks → Performance indicators
- Performance Gap = Expected minus observed care

# Sources of Performance Indicator Data

## National Surveys/Reports

### Behavior

– Public/Patient

– Provider

– Delivery System

### Data Sources

U.S. – NHIS, NHANES, BRFSS, MEPS  
LMIC – ?

U.S. – NAMCS; NHAMCS  
LMIC – ?

U.S. – NHDS, NCQA; Hospital Compare  
LMIC – ?

NHIS: National Health Information Survey  
NHANES: national Health and Nutrition Examination Survey  
BRFSS: Behavioral Risk Factor Surveillance System  
MEPS: Medical Expenditure Panel Survey

NAMCS: National Ambulatory Medical Care Survey  
NHAMCS: National Hospital Ambulatory Medical Care Survey  
NHDS: National Hospital Discharge Survey  
NCQA: National Center for Quality Assurance

# Example: Delivery system performance indicator data

## National Committee for Quality Assurance

### HEDIS Performance Indicator

- Beta-blocker for 6 months post MI
- Breast cancer screening
- Colorectal cancer screening
- Controlling high BP
- Comprehensive diabetes care
- Cholesterol management
- Chlamydia screening
- Spirometry testing for COPD

### Performance gap

10-19%  
26-42%  
36-43%  
36-43%  
36-55%  
42-60%  
49-62%  
57-69%

2014 State of Healthcare Quality Report, [www.ncqa.org](http://www.ncqa.org)

# Performance indicator data not available?

- Measure it yourself
- Example: What proportion of patients presenting to community health centers in Uganda are evaluated for TB in accordance with guidelines
  - Developed indicators to reflect guideline-recommended care
  - Collected data to assess indicators at 6 health centers in Uganda



## Example: Adherence to guidelines for TB evaluation

Q1 2009 (14,852 patients → 365 with cough $\geq$ 2 weeks)		
Performance Indicator	Observed	Gap
Indicator 1: Referred for TB testing	21%	79%
Indicator 2: Completed TB testing (if referred)	71%	29%
Indicator 3: Treated for TB (if smear-positive)	73%	27%
Guideline-adherent care	11%	89%

Davis JL. AJRCCM 2011

# Measuring Quality When No Guidelines Exist

- Analysis of variation in clinical practice
  - Country to Country
  - Region to Region
  - Across different healthcare facilities
- Why practice variation?
  - Wide variation unlikely due to illness severity or patient factors
  - Reflects clinical practice that is idiosyncratic and/or unscientific


# Sources of practice variation data

## Administrative claims data

*– Administrative data collected as a result of “claims” submitted by physicians/practices for reimbursement.*

- Medicare (UB-92): No pharmacy data
- Medicaid (Drug Utilization Review)
- Integrated Delivery Systems (Kaiser; Geisinger; etc)
- Managed Care Organizations


# Example: Administrative Claims Data




-from Dartmouth Atlas: [www.dartmouthatlas.org](http://www.dartmouthatlas.org)

# Claims Data Not Available?

- Measure variation yourself




# Link Performance Gap to an Outcome Gap



# Link practice variation data to an outcome of interest

**Antibiotic utilization = Antibiotic resistance**



**Figure 6: Correlation between penicillin use and prevalence of penicillin non-susceptible *S pneumoniae***  
AT, Austria; BE, Belgium; HR, Croatia; CZ, Czech Republic; DK, Denmark; FI, Finland; FR, France; DE, Germany; HU, Hungary; IE, Ireland; IT, Italy; LU, Luxembourg; NL, The Netherlands; PL, Poland; PT, Portugal; SI, Slovenia; ES, Spain; UK, England only.

# The public health and business case

**FIGURE 10. AVOIDABLE DEATHS AND MEDICAL COSTS DUE TO UNEXPLAINED VARIATIONS IN CARE: SELECT MEASURES AND CONDITIONS, U.S. POPULATION, 2006**

MEASURE	AVOIDABLE DEATHS	AVOIDABLE HOSPITAL COSTS
Beta-Blocker Treatment After a Heart Attack	500 - 1,200	\$6.1 million - \$10.8 million
Breast Cancer Screening	200 - 700	\$89 million
Cervical Cancer Screening	600 - 800	N/A
Cholesterol Management	4,400 - 9,400	\$20.1 million - \$60.9 million
Colorectal Cancer Screening	6,000 - 12,600	\$284 million - \$411 million
Controlling High Blood Pressure	9,200 - 22,800	\$292 million - \$708 million
Diabetes Care - HbA1c Control	7,100 - 15,900	\$1.3 billion - \$1.7 billion
Osteoporosis Management	N/A	\$9.9 million - \$10.4 million
Prenatal Care	1,000 - 1,600	N/A
Smoking Cessation	7,000 - 10,700	\$673 million - \$725 million
<b>TOTAL</b>	<b>35,000 - 75,000</b>	<b>\$2.7 billion - \$3.7 billion</b>



# Evidence-Practice Gap Summary

- Frame evidence as a quality of care issue - Improving the quality of care (*i.e.*, translation of your evidence) should maximize
  - Safety, effectiveness, efficiency, patient-centeredness, and timeliness and eliminate disparities in care
- To make the case for **investing** in translating your evidence into practice
  - Measure current performance, determine the performance gap, and link the performance gap to an outcome gap